Marburg Virus Outbreak: Rwanda Reports 20 Cases

Updated Sep 30, 2024 | 09:08 AM IST

SummaryThe latest outbreak in Africa is in Rwanda, it is the Marburg virus which have so far killed 6 people. Read on to know more about it.
Marburg Virus

Credits: Canva

After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

End of Article

US FDA Approves First Drug To Cut Death Risk By 55% In Niemann-Pick Patients: What Is The Rare Disease?

Updated Nov 18, 2026 | 07:02 AM IST

SummaryNiemann-Pick disease type C (NPC) is a rare inherited disorder that affects the body's ability to process cholesterol. Lembaz addresses this underlying cause, extending life expectancy.
US FDA Approves First Drug To Cut Death Risk By 55% In Niemann-Pick Patients: What Is The Rare Disease?

Credit: AI image

The US Food and Drug Administration (FDA) has granted approval to a new drug that could help patients with a rare and life-threatening genetic disorder live longer. The treatment, Lembaz (adrabetadex), is the first drug proven to reduce the risk of death in patients with infantile-onset Niemann-Pick disease type C (NPC).

Announced on November 17, 2026, the approval marks an important development for families affected by the rare disease, which causes progressive neurological damage and can significantly shorten life expectancy.

Lembaz is approved for adults and children weighing at least 7 kg (approximately 15 pounds) whose neurological symptoms began before the age of six. It is administered as an injection directly into the fluid surrounding the spinal cord, a procedure known as an intrathecal injection, every two weeks.

"For the first time, there is a treatment shown to help adults and children with this serious disease live longer," said Acting FDA Commissioner Kyle Diamantas.

Lembaz Reduces Risk Of Death By 55% In Niemann-Pick Patients

Also read: Trials For Deadly Childhood Brain Cancer Stalled After Trump Administration Shuts Down 27-Year Research Consortium

The FDA's approval was based on data from 36 patients treated with Lembaz across three clinical studies. Their outcomes were compared to an external control group of patients who had not received the treatment.

The analysis found that patients who received Lembaz had a 55% lower risk of death compared to the control group.

The median overall survival was 8.5 years among patients treated with Lembaz compared to 4.9 years in the control group.

The benefit was observed regardless of whether patients were also receiving miglustat, another medicine used to manage NPC.

What Is Niemann-Pick Disease Type C?

Also read: Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Niemann-Pick disease type C is a rare inherited disorder that affects the body's ability to process cholesterol and other fatty substances inside cells.

The condition is caused by changes in either the NPC1 or NPC2 gene. These genes produce proteins that help move cholesterol and other lipids within cells. When these proteins do not function properly, fatty substances accumulate inside cells, affecting organs like liver, spleen and brain. Over time, this causes progressive damage to the nervous system.

Patients may experience difficulties with movement, balance, coordination, speech and swallowing. Some may also face seizures, cognitive difficulties and problems controlling eye movements.

The disease affects approximately one in 150,000 people, according to the FDA. Its symptoms and severity can vary depending on when the disease begins.

Infantile-Onset Niemann-Pick Disease Can Be Severe

Also read: 112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Infantile-onset NPC refers to cases in which neurological symptoms start before the age of six. These patients experience a more aggressive disease as they face rapid progressive neurological deterioration and a shorter life expectancy.

As the disease advances, children may gradually lose the ability to walk, speak and swallow independently. Difficulties with swallowing can also increase the risk of respiratory complications.

There is currently no cure for NPC, making treatments that can slow disease progression or improve survival important.

More About Lembaz

Lembaz contains adrabetadex, a cyclodextrin-based medicine made to address the underlying cholesterol processing defect in NPC.

In simple terms, the drug helps move cholesterol trapped inside cells, especially brain cells, so that it can be transported to areas where it is needed.

By targeting this underlying problem, the treatment aims to reduce the cellular damage that comes with the disease.

According to the FDA, hearing impairment, including permanent hearing loss, could be one of the side effects of Lembaz. Hence, patients must undergo hearing assessments before starting the drug and regularly throughout the course.

Other common side effects include balance and coordination problems, fatigue, vomiting, back pain, headache, fever, diarrhoea, nausea and cough.

End of Article

112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Updated Nov 18, 2026 | 02:00 AM IST

SummarySummary: A CDC-led report identified 112 measles infections among pregnant women and 13 cases of congenital measles in newborns in the US between January 2025 and September 2026. Nearly all infected women were unvaccinated or had an unknown vaccination status, highlighting the risks of declining immunization amid ongoing outbreaks.
112 Pregnant Women, 13 Newborns Infected With Measles In US Since 2025: CDC

Credit: AI Image

The US has lost its measles elimination status after 26 years, with Bolivia and Mexico also losing the designation, the Pan American Health Organization (PAHO) announced on Tuesday. The decision follows more than 12 months of continuous measles transmission in the US.

Amid the resurgence, a CDC-led report has identified 112 measles infections among pregnant women in the US between January 2025 and September 2026, along with 13 cases of congenital measles in newborns. Nearly all the women were unvaccinated or had an unknown vaccination status.

The actual number of infections among pregnant women may be higher. A separate CIDRAP News investigation based on state health department data identified at least 167 pregnant women infected in 2025 and 2026.

Measles In Unvaccinated Women

Also Read: What Happens After Measles Infection? The Hidden Risks That Can Last For Years

The CDC-led report, published in NEJM Evidence journal, found that 108 (96%) of the 112 cases occurred during outbreaks involving 50 or more cases.

Of the infected women, 110 (98%) had received no MMR vaccine doses or had an unknown vaccination status.

Twenty-six women (23%) were hospitalized for reasons unrelated to childbirth, while 11 (10%) developed pneumonia.

“Even though measles is an old disease, measles in pregnancy is an emerging area that we need to learn about,” said Michelle Barton, a professor at the Schulich School of Medicine & Dentistry at Western University.

Measles In Newborns

Read More: Congenital Measles Reported In Pennsylvania For First Time In Decades: What Parents Should Know

The report recorded 21 pregnancy outcomes within 14 days of maternal rash onset: 19 live births and two pregnancy losses, including one miscarriage and one stillbirth.

Eight babies were born prematurely, and eight required admission to a neonatal intensive care unit (NICU).

The report noted that 13 babies had congenital measles and tested positive for the virus. Of these, six developed symptoms, including one with signs compatible with meningoencephalitis, a potentially life-threatening inflammation of the brain and surrounding membranes.

The authors said the outbreaks highlighted measles' risks to maternal and newborn health.

Many doctors and nurses treating these patients have never encountered measles, relying largely on medical training and professional guidelines to manage the infections.

The CDC recommends intravenous immunoglobulin as post-exposure prophylaxis for pregnant women without documented MMR vaccination or other evidence of immunity who are exposed to measles.

Newborns exposed to measles in the womb should also receive immunoglobulin at birth. Congenital measles can cause severe neurological complications, including subacute sclerosing panencephalitis (SSPE), a rare, progressive brain disorder.

US Loses Measles Elimination Status After 26 Years

The US is experiencing its highest measles burden in more than three decades. Since 2025, approximately 7,700 people have been infected and 13 have died, according to the figures cited in the report.

As of November 12, the CDC had confirmed 5,412 cases and six deaths in 2026. States had reported 10 deaths.

The rise in infections has coincided with declining vaccination rates and growing vaccine hesitancy. US Health Secretary Robert F. Kennedy Jr. has repeatedly questioned measles vaccine safety without scientific evidence supporting those claims.

The CDC said it would work to stop outbreaks and regain elimination status by supporting states and providing sustained national leadership.

"The measles elimination designation is not what protects Americans; vaccination does," CDC Director Erica Schwartz said.

End of Article

Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Updated Nov 17, 2026 | 11:30 PM IST

SummaryNovo Nordisk led trial found that Wegovy reduced BMI by at least 10% in nearly 80% of children aged 6 to under 12 with obesity. However, limited long-term safety data and concerns about appetite suppression, nutritional intake and childhood development raise questions about the use of semaglutide in younger children.
Childhood Obesity: Wegovy Cuts BMI By 10% In Children As Young As 6; What Are The Risks?

Credit: AI Image

A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.

The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.

However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.

What Did The STEP Young Trial Find?

Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?

The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.

The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.

After 68 weeks:

  • BMI decreased by 17.4% with semaglutide.
  • BMI increased by 2.2% with placebo.
  • 83% of children receiving semaglutide improved their BMI category, compared with 23.5% receiving placebo.
  • 40.4% were no longer classified as having obesity, compared with none in the placebo group, under the efficacy estimand.
More than 85% of participants had severe obesity at the start of the trial.

Why Do The Findings Matter?

Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.

The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.

"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.

What Are The Side Effects?

Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year

Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.

Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.

Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.

WHO Advises Against Weight-Loss Drugs For Children Under 10

The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.

Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.

For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.

Risks Of GLP-1 Use in Children

Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report

Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.

A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.

The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.

However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.

It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.

Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.

End of Article